



(43) International Publication Date  
3 September 2009 (03.09.2009)

(10) International Publication Number  
**WO 2009/108147 A1**

- (51) International Patent Classification:  
*A61K 8/02* (2006.01)
- (21) International Application Number:  
PCT/US2008/002549
- (22) International Filing Date:  
27 February 2008 (27.02.2008)
- (25) Filing Language: English
- (26) Publication Language: English
- (71) Applicant (for all designated States except US): **QLT USA, INC.** [US/US]; 2579 Midpoint Drive, Fort Collins, CO 80525-4417 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **GARRETT, John Steven** [US/US]; 7113 Silver Moon Lane, Fort Collins, CO 80252 (US).
- (74) Agents: **STEFFEY, Charles E.** et al.; Schwegman, Lundberg & Woessner, PA, P.O. Box 2938, Minneapolis, Minnesota 55402 (US).

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report (Art. 21(3))

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) Title: DAPSONE TO TREAT ROSASCEA




FIG. 11

(57) Abstract: The methods described herein provide treatment of rosacea using topical formulations of dapsone. The methods also provide treatment of rosacea with topical dapsone in combination with other active agents, including metronidazole. The methods avoid negative hematologic side effects, including hemolysis and hemolytic anemia, that are associated with oral administration of dapsone.

WO 2009/108147 A1

## **DAPSONE TO TREAT ROSACEA**

5

### **Background of the Invention**

Rosacea is a dermatological syndrome affecting approximately 14 million Americans. It is characterized by flushing of the skin, erythema, inflammatory papules and pustules, edema, telangiectasia, ocular symptoms and rhinophyma. To date, the etiology of rosacea is unknown and there is no clearly  
10 recognized cure (Bikowski and Goldman, 2004; Stone and Chodosh, 2004).

Four subtypes and one variation of rosacea have been defined. The subtypes are papulopustular rosacea, erythematotelangiectatic rosacea, phymatous rosacea, and ocular rosacea; the rosacea variation is granulomatous rosacea. Some patients may have features of more than one subtype  
15 simultaneously, and differences in severity occur within each subtype.

Management of rosacea is difficult because of the complexity of the syndrome and the sensitivity of rosacea-affected skin. Various therapies, including topical application of metronidazole, azelaic acid, sodium sulfacetamide/sulfur preparations, and antibiotics including erythromycin, clindamycin and tetracycline, are used in the management of rosacea with  
20 varying rates of success. Systemic therapy with oral tetracyclines, metronidazole and isotretinoin is also employed in the management of rosacea (Buechner, 2005). Dapsone antibiotic is effective for treating rosacea redness, facial flushing, papules and pustules when administered orally; however, the side  
25 effect profile makes the risk/benefit ratio too high for most rosacea sufferers (Nase, 2005).

What is needed are safe, effective treatments for the management of rosacea symptoms.

30

### **Summary of the Invention**

The invention is directed to the treatment of rosacea. The invention includes a method to treat rosacea by topically administering a pharmaceutical composition of dapsone and a pharmaceutically acceptable carrier to a patient. In preferred embodiments, the rosacea is papulopustular rosacea. In other  
35 embodiments, the rosacea is ocular rosacea. The invention is also directed to the

treatment of ocular disorders. The invention includes a method to treat an ocular disease or disorder by topically administering a pharmaceutical composition of dapsone and a pharmaceutically acceptable carrier.

In some embodiments, the dapsone of the topical composition is entirely  
5 dissolved in the carrier; or partially dissolved and partially microparticulate; or  
may be present as an emulsion, suspension or colloid. In an entirely dissolved  
state, dapsone exists completely in solution in the solvent, with no solid dapsone  
present. If the dapsone is partially dissolved and partially microparticulate, a  
portion of the dapsone is present in solution and a portion of the dapsone is  
10 present in a solid form. A dapsone emulsion includes two immiscible,  
unblendable substances wherein one substance (the dispersed phase) is dispersed  
in the other (continuous phase). The dapsone can be part of the dispersed phase  
or part of the continuous phase of the emulsion. A dapsone suspension is a  
heterogenous fluid containing solid particles of dapsone dispersed throughout a  
15 fluid. A dapsone colloid is a homogenous mixture of dispersed dapsone  
particles that are distributed evenly and stably throughout the continuous phase.

In certain embodiments, the pharmaceutical composition is a lotion, gel,  
ointment, cream, emulsion, suspension, spray, or cleanser. In a preferred  
embodiment, the pharmaceutical composition is a semisolid aqueous gel. The  
20 semisolid aqueous gel includes a thickening agent, water, a solvent, preservative,  
microparticulate dapsone, dissolved dapsone, and caustic material. In a  
preferred embodiment, the caustic material is a base agent. In a preferred  
embodiment, the composition exhibits an optimal balance between dissolved  
dapsone that is available to cross through the stratum corneum of the epidermis  
25 and be absorbed into the lower two-thirds of the pilosebaceous unit; and  
microparticulate dapsone that is retained in or above the stratum corneum to  
serve as a reservoir or to provide dapsone to the supracorneum zone, crossing the  
stratum corneum of the epidermis only minimally as a solid. The solid  
microparticulate dapsone reservoir is slowly dissolved in body fluids before it is  
30 delivered through the stratum corneum. In preferred embodiments, the dapsone  
makes up about 0.5% to 10% of the pharmaceutical composition. The  
microparticulate dapsone can be a crystalline precipitate or an amorphous  
precipitate. Antioxidants, fragrance, colorants, sunscreens, or combinations  
thereof may also be present in the topical composition. In preferred

embodiments, the dapsones composition comprises about 5% dapsones, about 0.85% carbomer 980, about 25% diethylene glycol monoethyl ether (DGME), about 0.2% methylparaben, about 0.2% sodium hydroxide, and about 68.75% purified water.

5           The methods described herein include the treatment of papulopustular rosacea by applying the dapsones composition once or twice daily. In preferred methods the dapsones composition is applied twice daily. The methods additionally include the use of the dapsones pharmaceutical composition alone or in combination with other pharmaceutical compositions for rosacea, including  
10   topical and systemic treatments. The treatments are administered simultaneously or sequentially and include oral metronidazole, isotretinoin, tetracyclines including doxycycline, and topical metronidazole, azelaic acid, sodium sulfacetamide/sulfur preparations, and antibiotics including erythromycin, clindamycin and tetracycline. In some embodiments, the dapsones and other  
15   pharmaceutical are present in the same composition. In other embodiments, the dapsones and other pharmaceutical are present in separate compositions. In preferred embodiments, the dapsones pharmaceutical composition is applied topically in the AM and a separate metronidazole composition is applied topically in the PM, or vice versa.

20           In some embodiments, the patient has mild to severe papulopustular rosacea. In some embodiments, the patient has mild to moderate papulopustular rosacea. In other embodiments, the patient has moderate to severe papulopustular rosacea. In preferred embodiments, the rosacea is moderate to severe papulopustular rosacea. In some embodiments, the patient has at least ten  
25   papulopustular lesions before treatment, or preferably at least twenty papulopustular lesions before treatment. In a preferred embodiment, the number of papulopustular rosacea lesions is reduced by administering the dapsones composition topically. In some embodiments, the methods described herein result in blood plasma levels of dapsones of less than about 100 ng/mL.

30           In some embodiments, the patient has an Investigator's Global Assessment score of 3 or higher before treatment. In some embodiments, treatment results in a mean reduction of at least 13 papulopustular lesions. In some embodiments, treatment results in a mean reduction of at least 43 % of the papulopustular lesions.

### **Brief Description of the Figures**

5 Figure 1 shows the mean change from baseline in inflammatory lesion counts in the intent to treat (ITT) population having  $\geq 10$  inflammatory lesions (papules and/or pustules) above the mandibular line.

Figure 2 shows the mean percent change from baseline in inflammatory lesion counts in the ITT population having  $\geq 10$  lesions (ITT).

Figure 3 shows mean change from baseline in inflammatory lesion counts for subjects with  $<20$  lesions.

10 Figure 4 shows mean percent change from baseline in inflammatory lesion counts for subjects with  $<20$  lesions.

Figure 5 shows the mean change from baseline in lesion counts for the subgroup of subjects with  $\geq 20$  lesions.

15 Figure 6 shows mean percent change from baseline in inflammatory lesion counts for subjects with  $\geq 20$  lesions.

Figure 7 shows the Investigator's Global Assessment (IGA) success rate over the course of the study in the intent to treat (ITT) population having  $\geq 10$  inflammatory lesions.

20 Figure 8 summarizes the Investigator's Global Assessment (IGA) success rate at week 12 in the intent to treat (ITT) population having  $\geq 10$  inflammatory lesions.

Figure 9 shows the Investigator's Global Assessment (IGA) success rate over the course of the study in subjects with  $<20$  inflammatory lesions.

25 Figure 10 shows the Investigator's Global Assessment (IGA) success rate over the course of the study in subjects with  $\geq 20$  lesions.

Figure 11 summarizes the Investigator's Global Assessment (IGA) success rate at week 12 for the subgroup of subjects with  $\geq 20$  lesions.

### **Detailed Description of the Invention**

#### 30 Definitions

As used herein, "adverse event" means any adverse change in health or "side-effect" that occurs in a patient who is participating in a study while the patient is receiving treatment (dermatological composition or vehicle) or within a pre-specified period of time after their treatment has been completed.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.